Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

Many biotechnology companies don't have approved products on the market, so they don't generate reliable revenue. From time ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business ...

Biden Administration says that manufacturers of sickle cell gene therapies agree to participate in access model in 2025.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...

CRISPR Therapeutics' Q3 saw reduced expenses and slow Casgevy launch, resulting in a revenue miss. Read why I am neutral on ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...